Supriya Lifescience Q4 FY26 Investor Presentation: Revenue Up 50% YoY to ₹2,765 Crore
Supriya Lifescience reported Q4 FY26 revenue of ₹2,765.3 million, a 50.2% YoY increase. Full-year FY26 revenue reached ₹8,278.7 million, up 18.9% YoY. Q4 FY26 PAT was ₹742.3 million (up 47.4% YoY), and FY26 PAT was ₹2,091.2 million (up 11.3% YoY). The company highlighted export strength and R&D focus.
Significant revenue and profit growth, coupled with a detailed investor presentation outlining future strategies and performance metrics, will likely have a material impact on investor perception and the company's stock.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT for both the quarter and the full fiscal year, indicating positive financial performance.
Supriya Lifescience Limited has released its investor presentation for the fourth quarter and full year ended March 31, 2026. The company reported a significant 50.2% year-on-year increase in revenue from operations for Q4 FY26, reaching ₹2,765.3 million (₹276.53 crore).
For the full fiscal year FY26, revenue grew by 18.9% YoY to ₹8,278.7 million (₹827.87 crore). EBITDA for Q4 FY26 surged by 44.4% to ₹976.2 million (₹97.62 crore), and for FY26, it increased by 12.8% to ₹2,940.5 million (₹294.05 crore). Profit After Tax (PAT) for Q4 FY26 rose by 47.4% to ₹742.3 million (₹74.23 crore), while full-year PAT increased by 11.3% to ₹2,091.2 million (₹209.12 crore).
The presentation highlights strong performance across key therapeutic areas and a diversified geographic presence, with 82% of FY26 revenue coming from exports. The company continues to focus on expanding its API and finished dosage formulations, with strategic investments in R&D and manufacturing capabilities. Supriya Lifescience also emphasized its backward-integrated business model, which contributes significantly to its revenue growth and margin resilience.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.